A-Shine s.r.o.
- Address
- lock Available on a paid plan
A-Shine s.r.o. - Neuroscience and Cognitive Disorders Research Center
A-Shine s.r.o. is a specialized clinical research facility focused on advancing treatments for neurological and psychiatric conditions. The center demonstrates particular expertise in cognitive disorders and neurodegenerative diseases, conducting pivotal clinical trials that address some of the most challenging conditions affecting mental health and cognitive function.
- Cognitive impairment associated with schizophrenia and psychiatric disorders
- Alzheimer's disease and mild cognitive impairment (MCI)
- Schizophrenia treatment optimization and adjunctive therapies
- Migraine prevention and comparative safety studies
The research portfolio at A-Shine s.r.o. encompasses comprehensive phase II and III clinical trials evaluating both novel therapeutics and comparative treatment approaches. The center's capabilities include rigorous assessment of cognitive performance measures, safety evaluations using standardized scales such as the Clinical Dementia Rating-Sum of Boxes (CDR-SB), and tolerability comparisons between emerging and established therapies. With expertise spanning from chronic and episodic migraine prevention to complex neurodegenerative conditions, A-Shine s.r.o. contributes valuable clinical evidence to improve patient outcomes across the neuroscience therapeutic spectrum.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 31 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Neurocrine Biosciences Inc.4trials
lock +10 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in A-Shine s.r.o.
lock Showing 1 of 39 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, Multicenter, Randomized, Double blind, Placebo controlled Trial of the Safety and Efficacy of Flexible Doses of SEP 363856 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder. | Otsuka Pharmaceutical Development & Commercialization Inc. | Phase IV | Not Recruiting | Mar 2023 | Nov 2025 |
IMP list
lock Showing 1 of 31 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Trospium Chloride | 4 | Unknown | 2024-05-09 | 2026-06-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.